Michael G. Grey's most recent trade in Mirum Pharmaceuticals Inc was a trade of 3,772 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mirum Pharma Inc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2026 | 3,772 | 3,772 | - | - | Stock Option (right to buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2026 | 1,980 | 1,980 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 1,700 | 1,700 | - | - | Stock Option (Right to Buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 78.00 per share. | 19 Dec 2025 | 50,000 | 0 (0%) | 0% | 78 | 3,900,000 | Common Stock |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 19 Dec 2025 | 50,000 | 50,000 (0%) | 0% | 2.9 | 146,800 | Common Stock |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2025 | 50,000 | 181,176 | - | - | Stock Option (right to buy) | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Dec 2025 | 1,499 | 0 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 1,499 | 1,499 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Dec 2025 | 1,255 | 0 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 1,255 | 1,255 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Dec 2025 | 666 | 0 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 666 | 666 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Dec 2025 | 400 | 0 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 400 | 400 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 387 | 387 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Dec 2025 | 387 | 0 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 133 | 133 | - | - | Stock Option (right to buy) | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Dec 2025 | 133 | 0 | - | - | Stock Option (right to buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 01 Dec 2025 | 50,000 | 50,000 (0%) | 0% | 2.9 | 146,800 | Common Stock |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 50,000 | 231,176 | - | - | Stock Option (right to buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 74.00 per share. | 01 Dec 2025 | 50,000 | 0 (0%) | 0% | 74 | 3,700,000 | Common Stock |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 21 Nov 2025 | 50,000 | 50,000 (0%) | 0% | 2.9 | 146,800 | Common Stock |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 50,000 | 281,176 | - | - | Stock Option (right to buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 21 Nov 2025 | 50,000 | 0 (0%) | 0% | 70 | 3,500,000 | Common Stock |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 6,268 | 6,268 | - | - | Stock Option (right to buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 3,977 | 3,977 | - | - | Deferred Stock Units | |
| Mirum Pharma Inc | Michael G. Grey | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Sep 2024 | 102,788 | 186,410 (0%) | 0% | 0 | Common Stock | |
| Mirum Pharma Inc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 8,779 | 8,779 | - | - | Stock Option (right to buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 5,703 | 5,703 | - | - | Deferred Stock Units | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2023 | 14,216 | 331,176 | - | - | Stock Option (right to buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 13 Sep 2023 | 14,216 | 14,216 (0%) | 0% | 2.9 | 41,738 | Common Stock |
| Mirum Pharma Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 32.00 per share. | 13 Sep 2023 | 14,216 | 0 (0%) | 0% | 32 | 454,912 | Common Stock |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2023 | 392 | 345,392 | - | - | Stock Option (right to buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 13 Sep 2023 | 392 | 392 (0%) | 0% | 2.9 | 1,151 | Common Stock |
| Mirum Pharma Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 32.00 per share. | 13 Sep 2023 | 392 | 0 (0%) | 0% | 32 | 12,544 | Common Stock |
| Mirum Pharma Inc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 08 Jun 2023 | 14,608 | 14,608 (0%) | 0% | 2.9 | 42,889 | Common Stock |
| Mirum Pharma Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 29.00 per share. | 08 Jun 2023 | 14,608 | 0 (0%) | 0% | 29 | 423,632 | Common Stock |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2023 | 14,608 | 345,784 | - | - | Stock Option (right to buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2023 | 14,608 | 360,392 | - | - | Stock Option (right to buy) | |
| Mirum Pharma Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 03 May 2023 | 14,608 | 14,608 (0%) | 0% | 2.9 | 42,889 | Common Stock |
| Mirum Pharma Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 03 May 2023 | 14,608 | 0 (0%) | 0% | 28 | 409,024 | Common Stock |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 3,913 | 0 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 3,913 | 19,361 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 4,223 | 0 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 4,223 | 66,513 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2022 | 3,913 | 3,913 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.56 per share. | 28 Apr 2022 | 1,139 | 65,374 (0%) | 0% | 98.6 | 112,260 | Ordinary Shares |